Skip to main content

Table 1 Correlations between CCN3/SMA and clinicopathology feature in 86 patients with HCC

From: Remodeling of hepatic stellate cells orchestrated the stroma-derived oxaliplatin-resistance through CCN3 paracrine in hepatocellular carcinoma

Variable

No. of Patient

 

No. of Patient

 

CCN3high

CCN3low

p

SMA high

SMA low

p

Age, y

 ≥ 53

14

25

0.419

18

21

0.397

 <53

19

28

 

26

21

 

Sex

 Men

26

44

0.624

36

34

0.918

 Women

7

9

 

8

8

 

HBsAg

 Positive

30

48

0.958*

39

39

0.501*

 Negative

3

5

 

5

3

 

Cirrhosis

 Yes

29

46

0.883*

42

34

0.085*

 No

4

7

 

2

9

 

Serum, AFP

 ≥ 20

21

32

0.762

29

24

0.403

 <20

12

21

 

15

18

 

Serum, ALT

 ≥ 75

11

27

0.110

15

23

0.053

 <75

22

26

 

29

19

 

Tumor dimension

 ≥ 5 cm

9

4

0.013

10

3

0.044*

 <5 cm

24

49

 

34

39

 

No. of tumors

 Multiple

4

2

0.139*

3

3

0.953*

 Single

29

51

 

41

39

 

Vascular invasion

 Yes

9

4

0.023*

7

6

0.834

 No

24

49

 

37

36

 

Tumor encapsulation

 Complete

8

27

0.014

12

23

0.009

 None

25

26

 

32

19

 
  1. For CCN3, and SMA median values were used as cut-off points for definition of subgroups (low expression and high expression groups)
  2. *Fisher’s exact tests, and Chi-square tests for all other analyses
  3. Boldface in table indicates the difference has statistical significance (p<0.05)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us